Physician profile
Robert Parrott
NPI 1508827700
$14,936.01
in general payments reported to CMS, 2019-2025
61 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $1,583 · 2021: $1,811 · 2022: $2,399 · 2023: $2,585 · 2024: $2,362 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,324 · Education: $60.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,323.55 |
| Education | $60.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,791.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $1,352.46 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $1,298.21 | 2019-2025 | |
| Abbvie INC. | $1,215.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,029.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,001.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $760.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $553.08 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Horizon Therapeutics Plc | $413.00 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $411.07 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $362.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.99 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $327.80 | 2019-2023 | Trintellix |
| Dexcom, INC. | $323.20 | 2021-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $309.38 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Parrott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.